Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial

Autor: Takashi Ito, Ikuro Maruyama, Shuji Shimazaki, Yasuhiro Yamamoto, Naoki Aikawa, Akio Hirayama, Goichi Honda, Hidehiko Saito

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 7, Pp 1141-1149 (2020)

Abstract Background The efficacy and safety of thrombomodulin alfa (TM‐α), a cofactor protein promoting thrombin‐mediated protein C activation, have been examined in a phase 3 randomized, double‐blinded, parallel‐group trial in Japan. We hav

Externí odkaz: https://doaj.org/article/d5ebd439b6bc4e76827a7b06f5e957e1

Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial

Autor: Akio Hirayama, Naoki Aikawa, Shuji Shimazaki, Hidehiko Saito, Goichi Honda, Yasuhiro Yamamoto, Ikuro Maruyama, Takashi Ito

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 7, Pp 1141-1149 (2020)
Research and Practice in Thrombosis and Haemostasis

Background The efficacy and safety of thrombomodulin alfa (TM-α), a cofactor protein promoting thrombin-mediated protein C activation, have been examined in a phase 3 randomized, double-blinded, parallel-group trial in Japan. We have previously repo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ac7e791ac8604dcf8a8df0b20b66bc
https://doaj.org/article/d5ebd439b6bc4e76827a7b06f5e957e1

Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.

Autor: Nobuaki Suzuki, Shinji Kunishima, Makoto Ikejiri, Shoichi Maruyama, Michihiko Sone, Akira Takagi, Masahito Ikawa, Masaru Okabe, Tetsuhito Kojima, Hidehiko Saito, Tomoki Naoe, Tadashi Matsushita

Publikováno v: PLoS ONE, Vol 8, Iss 8, p e71187 (2013)

Nonmuscle myosin heavy chain IIA (NMMHCIIA) encoded by MYH9 is associated with autosomal dominantly inherited diseases called MYH9 disorders. MYH9 disorders are characterized by macrothrombocytopenia and very characteristic inclusion bodies in granul

Externí odkaz: https://doaj.org/article/eda7cde0dd4a4735b108fa83d79831f3

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors

Autor: Teruhisa Fujii, Satoshi Higasa, Mitsuhiro Uchiba, Y. Ohashi, K. Fukutake, A. Tawa, Hideo Mugishima, Midori Shima, M. Migita, Y. Shinkoda, Akira Shirahata, K. Kawasugi, Hideji Hanabusa, Masashi Taki, Keiji Nogami, Yoshiyuki Kosaka, Hidehiko Saito, K. Sameshima, Tadashi Matsushita, K. Kawakami, Hideyuki Takedani, Junki Takamatsu, Michio Sakai

Publikováno v: Haemophilia. 23:59-66

Introduction MC710, a 1:10 protein weight ratio mixture of plasma-derived activated factor VII (FVIIa) and factor X (FX), is a novel bypassing agent for haemostasis in haemophilia patients with inhibitors. We evaluated the haemostatic efficacy and sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e604495d6605365e0cdec67ce7c0c834
https://doi.org/10.1111/hae.13050

The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis

Autor: Shuichi Taniguchi, Toru Masaoka, Heiwa Kanamori, Shunichi Kato, Yoshihisa Kodera, Fumimaro Takaku, Masaharu Ito, Hidehiko Saito, Shinichiro Okamoto, Minoko Takanashi

Publikováno v: Bone marrow transplantation. 53(5)

The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997361f438e4ae7623076debd5189b1b
https://pubmed.ncbi.nlm.nih.gov/29367710